Skip to main content
Figure 1 | Critical Care

Figure 1

From: Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial

Figure 1

Kaplan-Meier curve showing probability of survival during the first 28 days according to treatment group, among patients with sepsis. Dexmedetomidine decreased the probability of dying within 28 days by 70%; this beneficial effect was not seen in patients who were not septic (P value for interaction = 0.11 implying an interaction between sepsis and the treatment groups).

Back to article page